108 related articles for article (PubMed ID: 9607592)
41. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
[TBL] [Abstract][Full Text] [Related]
42. bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and bax.
Wang Y; Okan I; Szekely L; Klein G; Wiman KG
Cell Growth Differ; 1995 Sep; 6(9):1071-5. PubMed ID: 8519683
[TBL] [Abstract][Full Text] [Related]
43. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.
Ye S; Shen J; Choy E; Yang C; Mankin H; Hornicek F; Duan Z
Cancer Chemother Pharmacol; 2016 Feb; 77(2):349-56. PubMed ID: 26698867
[TBL] [Abstract][Full Text] [Related]
44. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways.
Fisher TC; Milner AE; Gregory CD; Jackman AL; Aherne GW; Hartley JA; Dive C; Hickman JA
Cancer Res; 1993 Jul; 53(14):3321-6. PubMed ID: 8324744
[TBL] [Abstract][Full Text] [Related]
45. p53-dependent apoptosis in melanoma cells after treatment with camptothecin.
Li G; Bush JA; Ho VC
J Invest Dermatol; 2000 Mar; 114(3):514-9. PubMed ID: 10692111
[TBL] [Abstract][Full Text] [Related]
46. Changes in p21WAF1, pRb, Mdm-2, Bax and Bcl-2 expression in cervical cancer cell lines transfected with a p53 expressing adenovirus.
Huang TG; Ip SM; Yeung WS; Ngan HY
Eur J Cancer; 2000 Jan; 36(2):249-56. PubMed ID: 10741285
[TBL] [Abstract][Full Text] [Related]
47. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea.
Aquilina G; Ceccotti S; Martinelli S; Soddu S; Crescenzi M; Branch P; Karran P; Bignami M
Clin Cancer Res; 2000 Feb; 6(2):671-80. PubMed ID: 10690553
[TBL] [Abstract][Full Text] [Related]
48. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.
Peters GJ; van Triest B; Backus HH; Kuiper CM; van der Wilt CL; Pinedo HM
Eur J Cancer; 2000 May; 36(7):916-24. PubMed ID: 10785598
[TBL] [Abstract][Full Text] [Related]
49. Wild-type p53 gene transfection in human cultured sarcomas: effect of CDDP.
Endo K; Kuratate I; Watanabe M; Yoshida H; Teshima R; Osaki M; Ito H
Oncol Rep; 2001; 8(3):637-42. PubMed ID: 11295094
[TBL] [Abstract][Full Text] [Related]
50. Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point.
Wang LH; Okaichi K; Ihara M; Okumura Y
Anticancer Res; 1998; 18(1A):321-5. PubMed ID: 9568097
[TBL] [Abstract][Full Text] [Related]
51. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines.
Burger H; Nooter K; Boersma AW; Kortland CJ; Stoter G
Int J Cancer; 1997 Nov; 73(4):592-9. PubMed ID: 9389577
[TBL] [Abstract][Full Text] [Related]
52. Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol.
Pepper C; Thomas A; Hoy T; Tighe J; Culligan D; Fegan C; Bentley P
Cell Cycle; 2003; 2(1):53-8. PubMed ID: 12695689
[TBL] [Abstract][Full Text] [Related]
53. Role of damage-sensing/processing genes in the radiation response of haemopoietic in vitro colony-forming cells.
Hendry JH; Hoyes KP; Wadeson P; Roberts SA
Int J Radiat Biol; 2002 Jul; 78(7):559-66. PubMed ID: 12079534
[TBL] [Abstract][Full Text] [Related]
54. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status.
De Feudis P; Debernardis D; Beccaglia P; Valenti M; Graniela Siré E; Arzani D; Stanzione S; Parodi S; D'Incalci M; Russo P; Broggini M
Br J Cancer; 1997; 76(4):474-9. PubMed ID: 9275024
[TBL] [Abstract][Full Text] [Related]
55. [Reversion of multidrug resistance in HL-60/VCR cells by down-regulation of bcl-2 with bcl-2 siRNA].
Piao Y; Chen XQ; Liu LM; Hong L; Liu JH; Zhou F; Liu YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1010-3. PubMed ID: 16403269
[TBL] [Abstract][Full Text] [Related]
56. Enhancement of the incorporation of 5-fluorodeoxyuridylate into DNA of HL-60 cells by metabolic modulations.
Tanaka M; Kimura K; Yoshida S
Cancer Res; 1983 Nov; 43(11):5145-50. PubMed ID: 6225512
[TBL] [Abstract][Full Text] [Related]
57. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.
Keshelava N; Zuo JJ; Waidyaratne NS; Triche TJ; Reynolds CP
Med Pediatr Oncol; 2000 Dec; 35(6):563-8. PubMed ID: 11107118
[TBL] [Abstract][Full Text] [Related]
58. [Inhibitory effect of combined transfection of p53 and AS genes on K562 cell proliferation].
Hu ZT; Zhu YY; Chen XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1173-6. PubMed ID: 18088460
[TBL] [Abstract][Full Text] [Related]
59. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2.
Miyake H; Hara I; Yamanaka K; Arakawa S; Kamidono S
J Urol; 1999 Dec; 162(6):2176-81. PubMed ID: 10569615
[TBL] [Abstract][Full Text] [Related]
60. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin.
Lam V; McPherson JP; Salmena L; Lees J; Chu W; Sexsmith E; Hedley DW; Freedman MH; Reed JC; Malkin D; Goldenberg GJ
Leuk Res; 1999 Oct; 23(10):871-80. PubMed ID: 10573131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
